Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes

Journal of Virology

Volumn 78, Issue 23, 2004, Pages 13037-13045

  Ferko, Boris ^a   Stasakova, Jana ^a   Romanova, Julia ^a   Kittel, Christian ^a   Sereinig, Sabine ^a   Katinger, Hermann ^a   Egorov, Andrej ^a  

^a UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD8 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INFLUENZA VACCINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MUTANT PROTEIN; PROTEIN NS1; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; GENE DELETION; GENE INSERTION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; INFECTION PREVENTION; INFLUENZA VIRUS A; LYMPHOCYTE COUNT; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROVOCATION TEST; RNA BINDING; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; VIRUS GENE; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE;

ANIMALS; BINDING SITES; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; CYTOKINES; DEFECTIVE VIRUSES; FEMALE; IMMUNIZATION; INFLUENZA A VIRUS; INFLUENZA VACCINES; INTERFERON-ALPHA; MICE; MUTATION; RNA; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 8644243888     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.23.13037-13045.2004     Document Type: Article

References (55)

1. Aragon, T., S. de la Luna, I. Novoa, L. Carrasco, J. Ortin, and A. Nieto. 2000. Eukaryotic translation initiation factor 4GI is a cellular target for NS1 protein, a translational activator of influenza virus. Mol. Cell. Biol. 20:6259-6268.
2. Asano, A., H. K. Jin, and T. Watanabe. 2003. Mouse Mx2 gene: organization, mRNA expression and the role of the interferon-response promoter in its regulation. Gene 306:105-113.
3. Belshe, R. B., W. C. Gruber, P. M. Mendelman, I. Cho, K. Reisinger, S. L. Block, J. Wittes, D. Iacuzio, P. Piedra, J. Treanor, J. King, K. Kotloff, D. I. Bernstein, F. G. Hayden, K. Zangwill, L. Yan, and M. Wolff. 2000. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136:168-175.
4. Belshe, R. B., W. C. Gruber, P. M. Mendelman, H. B. Mehta, K. Mahmood, K. Reisinger, J. Treanor, K. Zangwill, F. G. Hayden, D. I. Bernstein, K. Kotloff, J. King, P. A. Piedra, S. L. Block, L. Yan, and M. Wolff. 2000. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181:1133-1137.
5. Bergmann, M., A. Garcia-Sastre, E. Carnero, H. Pehamberger, K. Wolff, P. Palese, and T. Muster. 2000. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J. Virol. 74:6203-6206.
6. Beyer, W. E., A. M. Palache, J. C. de Jong, and A. D. Osterhaus. 2002. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy: a meta-analysis. Vaccine 20:1340-1353.
7. Boraschi, D., P. Bossu, G. Macchia, P. Ruggiero, and A. Tagliabue. 1996. Structure-function relationship in the IL-1 family. Front. Biosci. 1:d270-d308.
8. Boyaka, P. N., A. Tafaro, R. Fischer, K. Fujihashi, E. Jirillo, and J. R. McGhee. 2003. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity. Curr. Pharm. Des. 9:1965-1972.
9. Brydon, E. W., H. Smith, and C. Sweet. 2003. Influenza A virus-induced apoptosis in bronchiolar epithelial (NCI-H292) cells limits pro-inflammatory cytokine release. J. Gen. Virol. 84:2389-2400.
10. Cha, T. A., K. Kao, J. Zhao, P. E. Fast, P. M. Mendelman, and A. Arvin. 2000. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J. Clin. Microbiol. 38:839-845.
11. Cox, R. J., K. A. Brokstad, and P. Ogra. 2004. Influenza virus: immunity and vaccination strategies: comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59:1-15.
12. Donelan, N. R., C. F. Basler, and A. Garcia-Sastre. 2003. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J. Virol. 77:13257-13266.
13. Durbin, J. E., A. Fernandez-Sesma, C. K. Lee, T. D. Rao, A. B. Frey, T. M. Moran, S. Vukmanovic, A. Garcia-Sastre, and D. E. Levy. 2000. Type I IFN modulates innate and specific antiviral immunity. J. Immunol. 164:4220-4228.
14. Egorov, A., S. Brandt, S. Sereinig, J. Romanova, B. Ferko, D. Katinger, A. Grassauer, G. Alexandrova, H. Katinger, and T. Muster. 1998. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J. Virol. 72:6437-6441.
15. Ferko, B., D. Katinger, A. Grassauer, A. Egorov, J. Romanova, B. Niebler, H. Katinger, and T. Muster. 1998. Chimeric influenza virus replicating predominantly in the mutine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J. Infect. Dis. 178:1359-1368.
16. Ferko, B., J. Stasakova, S. Sereinig, J. Romanova, D. Katinger, B. Niebler, H. Katinger, and A. Egorov. 2001. Hyperattenuated recombinant influenza a virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 nef-specific systemic and mucosal immune responses in mice. J. Virol. 75:8899-8908.
17. Garcia-Sastre, A., A. Egorov, D. Matassov, S. Brandt, D. E. Levy, J. E. Durbin, P. Palese, and T. Muster. 1998. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252:324-330.
18. Geiss, G. K., M. Salvatore, T. M. Tumpey, V. S. Carter, X. Wang, C. F. Basler, J. K. Taubenberger, R. E. Bumgarner, P. Palese, M. G. Katze, and A. Garcia-Sastre. 2002. Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc. Natl. Acad. Sci. USA 99:10736-10741.
19. Gerdil, C. 2003. The annual production cycle for influenza vaccine. Vaccine 21:1776-1779.
20. Gorse, G. J., E. E. Otto, D. C. Powers, G. W. Chambers, C. S. Eickhoff, and F. K. Newman. 1996. Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly. J. Infect. Dis. 173:285-290.
21. Herlocher, M. L., A. C. Clavo, and H. F. Maassab. 1996. Sequence comparisons of A/AA/6/60 influenza viruses: mutations which may contribute to attenuation. Virus Res. 42:11-25.
22. Herlocher, M. L., H. F. Maassab, and R. G. Webster. 1993. Molecular and biological changes in the cold-adapted "master strain" A/AA/6/60 (H2N2) influenza virus. Proc. Natl. Acad. Sci. USA 90:6032-6036.
23. Horn, F., C. Henze, and K. Heidrich. 2000. Interleukin-6 signal transduction and lymphocyte function. Immunobiology 202:151-167.
24. Julkunen, I., K. Melen, M. Nyqvist, J. Pirhonen, T. Sareneva, and S. Malikainen. 2000. Inflammatory responses in influenza A virus infection. Vaccine 19:S32-S37.
25. Julkunen, I., T. Sareneva, J. Pirhonen, T. Ronni, K. Melen, and S. Matikainen. 2001. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev. 12:171-180.
26. Kaiser, L., R. S. Fritz, S. E. Straus, L. Gubareva, and F. G. Hayden. 2001. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J. Med. Virol. 64:262-268.
27. Kendal, A. P. 1997. Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur. J. Epidemiol. 13:591-609.
28. Kendal, A. P., H. F. Maassab, G. I. Alexandrova, and Y. Z. Ghendon. 1981. Development of cold-adapted recombinant live, attenuated influenza A vaccines in the USA and USSR. Antivir. Res. 1:339-365.
29. Kroemer, G., I. Moreno de Alboran, J. A. Gonzalo, and C. Martinez. 1993. Immunoregulation by cytokines. Crit. Rev. Immunol. 13:163-191.
30. Krug, R. M., W. Yuan, D. L. Noah, and A. G. Latham. 2003. Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology 309:181-189.
31. Le Bon, A., and D. F. Tough. 2002. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14:432-436.
32. Lee, S. W., J. W. Youn, B. L. Seong, and Y. C. Sung. 1999. IL-6 induces long-term protective immunity against a lethal challenge of influenza virus. Vaccine 17:490-496.
33. Luytjes, W., M. Krystal, M. Enami, J. D. Pavin, and P. Palese. 1989. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 59:1107-1113.
34. Maassab, H. F., and M. L. Bryant. 1999. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev. Med. Virol. 9:237-244.
35. Noah, D. L., K. Y. Twu, and R. M. Krug. 2003. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3′ end processing of cellular pre-mRNAS. Virology 307:386-395.
36. Palese, P., and A. Garcia-Sastre. 2002. Influenza vaccines: present and future. J. Clin. Investig. 110:9-13.
37. Power, C. A., C. L. Grand, N. Ismail, N. C. Peters, D. P. Yurkowski, and P. A. Bretscher. 1999. A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNγ-producing T cells. J. Immunol. Methods 227:99-107.
38. Proietti, E., L. Bracci, S. Puzelli, T. Di Pucchio, P. Sestili, E. De Vincenzi, M. Venditti, I. Capone, I. Seif, E. De Maeyer, D. Tough, I. Donatelli, and F. Belardelli. 2002. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immunol. 169:375-383.
39. Romanov Iu, R., A. Egorov, K. V. Lisovskaia, T. E. Medvedeva, G. N. Nevedomskaia, G. I. Aleksandrova, and A. I. Klimov. 1989. The effect of amplifying reproduction of influenza virus in mouse lungs during simultaneous infection with two cold-adapted strains. Vopr. Virusol. 34:547-553. (In Russian.)
40. Schlueter, A. J., A. M. Krieg, P. de Vries, and X. Li. 2001. Type I interferon is the primary regulator of inducible Ly-6C expression on T cells. J. Interferon Cytokine Res. 21:621-629.
41. Schumacher, B., D. Bernasconi, U. Schultz, and P. Staeheli. 1994. The chicken Mx promoter contains an ISRE motif and confers interferon inducibility to a reporter gene in chick and monkey cells. Virology 203:144-148.
42. Slifka, M. K., and J. L. Whitton. 2000. Clinical implications of dysregulated cytokine production. J. Mol. Med. 78:74-80.
43. Smith, E. J., I. Marie, A. Prakash, A. Garcia-Sastre, and D. E. Levy. 2001. IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or IκB kinase but is blocked by Vaccinia virus E3L protein J. Biol. Chem. 276:8951-8957.
44. Talon, J., C. M. Horvath, R. Polley, C. F. Basler, T. Muster, P. Palese, and A. Garcia-Sastre. 2000. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein J. Virol. 74:7989-7996.
45. Talon, J., M. Salvatore, O. N. Re, Y. Nakaya, H. Zheng, T. Muster, A. Garcia-Sastre, and P. Palese. 2000. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc. Natl. Acad. Sci. USA 97:4309-4314.
46. Tong, H. H., J. P. Long, P. A. Shannon, and T. F. DeMaria. 2003. Expression of cytokine and chemokine genes by human middle ear epithelial cells induced by influenza A virus and Streptococcus pneumoniae opacity variants. Infect. Immun. 71:4289-4296.
47. Treanor, J., M. Perkins, R. Battaglia, and B. R. Murphy. 1994. Evaluation of the genetic stability of the temperature-sensitive PB2 gene mutation of the influenza A/Ann Arbor/6/60 cold-adapted vaccine virus. J. Virol. 68:7684-7688.
48. Treanor, J. J., R. Buja, and B. R. Murphy. 1991. Intragenic suppression of a deletion mutation of the nonstructural gene of an influenza A virus. J. Virol. 65:4204-4210.
49. Wang, W., K. Riedel, P. Lynch, C. Y. Chien, G. T. Montelione, and R. M. Krug. 1999. RNA binding by the novel helical domain of the influenza virus NS1 protein requires its dimer structure and a small number of specific basic amino acids. RNA 5:195-205.
50. Wang, X., C. F. Basler, B. R. Williams, R. H. Silverman, P. Palese, and A. Garcia-Sastre. 2002. Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J. Virol. 76:12951-12962.
51. Watanabe, T., S. Watanabe, G. Neumann, H. Kida, and Y. Kawaoka. 2002. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J. Virol. 76:767-773.
52. Watkins, L. R., M. K. Hansen, K. T. Nguyen, J. E. Lee, and S. F. Maier. 1999. Dynamic regulation of the proinflammatory cytokine, interleukin-1beta: molecular biology for non-molecular biologists. Life Sci. 65:449-481.
53. Webster, R. G. 2000. Immunity to influenza in the elderly. Vaccine 18:1686-1689.
54. Yewdell, J., and A. Garcia-Sastre. 2002. Influenza virus still surprises. Curr. Opin. Microbiol. 5:414-418.
55. Zambon, M. C. 1999. Epidemiology and pathogenesis of influenza. J. Antimicrob. Chemother. 44(Suppl. B):3-9.